Alfasigma buys Nordic Pharma, adding Nordimet methotrexate and a women's-health/critical-care/ophthalmology portfolioFiercePharma • Aug 15 (date unconfirmed)A mid-tier specialty consolidation folding an established arthritis injectable and several specialty lines under one owner with new-market access is more branded-portfolio concentration than commodity read — but it reshapes which player holds which molecule franchise, the map a distributor's sourcing leverage runs across.
Taiho and Cullinan post a phase 3 win for their EGFR lung-cancer candidateFiercePharma • Aug 15 (date unconfirmed)Another late-stage read-out landing in high-cost targeted oncology — a patent-protected franchise with no generic or biosimilar pathway for a decade — marks where sector capital keeps concentrating, off the commodity base that fills most scripts.
GenericsEU strips Tavneos (avacopan) of its authorization, citing 'serious breaches' of pivotal-trial protocolFiercePharma • Aug 15 (date unconfirmed)A branded rare-disease complement inhibitor losing its EU marketing authorization over trial-conduct/data-integrity findings has no direct generic read (ex-US, patent-protected), but it pushes the same evidence-quality scrutiny that fills half the US supply board upstream to the pivotal trial itself — the layer regulators lean on when deciding what stays on the market.
GenericsAll three distributors' latest quarters confirm GLP-1 volume + specialty distribution — not the commodity base — are driving wholesaler marginMcKesson / Cencora / Cardinal earnings • Aug 5–11 2026MCK's North American drug-distribution operating profit rose 19% on 5% revenue with $15B of GLP-1 flow, COR's US Healthcare op income rose 16% on a $2.3B GLP-1 jump, and CAH's specialty book grew >25% — the Big 3 are converting on specialty/oncology buy-and-bill and GLP-1 pass-through while branded WAC cuts and branded-to-generic conversion compress the traditional generic-sourcing margin, so the profit is migrating up the value chain, not into the commodity generic base that fills most scripts.
GenericsCardinal Health's FQ4 EPS beat was flattered by a one-time $100M IEEPA tariff refund in its medical-distribution segmentCardinal Health / Zacks • Aug 11 2026The +40% adjusted-EPS print includes a $100M net operating-profit benefit from IEEPA tariff refunds booked in GMPD, and FY2027 guidance explicitly strips it out — a reminder that tariff mechanics are now moving distributor segment profit directly, the same import-duty machinery (0% to Aug 2028, then 100%/200%) that will eventually reprice the ~80%-imported-API generic base these wholesalers source.